Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
PanTracer™ LBx is now available! - Order now
The c-MET CDx for NSCLC test is a companion diagnostic indicated as an aid in identifying non-squamous NSCLC patients who may be eligible for treatment with EMRELIS™ (telisotuzumab vedotin-tllv). Eligibility for EMRELIS treatment includes high c-MET protein overexpression, defined as ≥50% of tumor cells with strong (3+) staining using this assay.
This test implements the VENTANA MET (SP44) RxDx Assay, a qualitative immunohistochemical assay using rabbit monoclonal anti-MET, clone SP44, intended for use in the assessment of MET protein in formalin-fixed paraffin embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) specimens. This test recognizes MET proto-oncogene, receptor tyrosine kinase (MET), also known as hepatocyte growth receptor and sometimes abbreviated as c-MET.
88360
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: July 17, 2025